Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Nordstjernan’s divestment of Salcomp finalized

As previously announced, (press release June 4, 2019), Nordstjernan has entered an agreement with Lingyi iTech regarding the divestment of Salcomp. The transaction was finalized on August 27 when closing took place. Peter HofvenstamPresident and CEONordstjernan AB   Questions will be answered by: Peter Hofvenstam, CEO, NordstjernanE-mail: peter.hofvenstam@nordstjernan.se Stefan Stern, Head of Communications, NordstjernanTelephone: +46 70 636 74 17 E-mail: stefan.stern@nordstjernan.se   Nordstjernan is a family-controlled investment

Q2 Report 2019 – invitation to conference call and audiocast

Today Thursday August 29, at 04.00 p.m. CET IRRAS will host a conference call and an online presentation of its Q2 2019 interim report (which was published earlier today at 08.00 a.m. CET).   The dial-in numbers for the conference call are:   Sweden: +46 8 5664 27 06 Rest of the world: +44 33 3300 9032  The presentation will also be webcast and can be accessed from the following web address: https://financialhearings.com/event/11741  Speakers: President CEO Kleanthis G. Xanthopoulos, Ph.D., CCO Will Martin and CFO Sabina Berlin    About IRRAS IRRAS AB (Nasdaq First

Interim report January – June 2019

Press release: Uppsala, August 29, 2019. Pharmacolog i Uppsala AB’s (publ) interim report for the period January - June is now available on the company’s webbsite www.pharmacolog.com (Swedish only)Andra kvartalet 1 april 2019 – 30 juni 2019 · Bolagets nettoomsättning för perioden uppgick till 1 750 (116) Tkr. · Rörelseresultatet för perioden uppgick till -3 670 (-3 700) Tkr. · Nettoresultat per aktie före och efter utspädning var för perioden -0,50 (-0,94) kr. Första halvåret 1 januari 2019 – 30 juni 2019 · Bolagets nettoomsättning för perioden uppgick till 2 100 (216)

Interim Report 01/01/2019 – 30/06/2019

Summary of quarter Q1-Q2 2019 The following summary refers to the period 1/1/2019 – 30/6/2019, compared to 1/1/2018 – 30/6/2018 · Net sales for this period totaled to SEK 3,097,362 (SEK 110,772)  · Operating result for the period of SEK -3,876,021 (SEK -4,324,984) · Cash and bank balance SEK 3,523,113 (SEK 11,019,147) · Capitalized development costs of SEK 783,251 (SEK 851,552) · Average number of registered shares 9,877,264 (9,877,264 shares) · Result per share* SEK -0.39 (SEK -0.44) · Equity Ratio 86.7% (91.8%) *Result per share is calculated on the average

Realfiction Holding AB announces its Q2 Interim Report for April – June 2019

The company announces that the Q2 Interim Report for April – June 2019 is now available. The full report is attached as a separate document and can also be downloaded from the company’s website (www.realfiction.com). A printed copy can be ordered via investor@realfiction.com. Below is a brief summary of the Q2 Interim Report.Important key figures: · •    7% decline in total revenue Q2, 2019 compared to Q2, 2018 · •    1% increase in gross profit in Q2, 2019 compared to Q2, 2018 · •    9% increase (4 points) in gross profit margin in Q2, 2019 compared to Q2, 2018 · •

Bioservo Technologies signs additional distribution agreement in Europe

Bioservo Technologies AB (publ) (Nasdaq First North: BIOS) has entered an exclusive distribution agreement for selling the all-new Ironhand® with awb Schraubtechnik- und Industriebedarf GmbHfor the Austrian market.Awb Schraubtechnik- und Industriebedarf GmbH is a well-known partner for industrial supply, tools and protective workwear in Austria. Due to increasing demand from their customers they have added an extensive range of exoskeletons to their portfolio, which now includes the Bioservo Ironhand. Amongst the company’s customers are Austrian subsidiaries of Siemens, BMW and similar

800 users, 1.3 million patients, 30 million images – one Planmeca Romexis® database

As the volumes of digital patient data increase in dentistry, so does the need for intelligent digital solutions for image handling and archiving. Planmeca’s uniquely comprehensive Planmeca Romexis® software platform can flexibly adapt to the imaging and diagnostic needs of clinics of any size – as evidenced by two textbook examples from Sweden. Dental care generates enormous amounts of patient data both over time and across multiple locations. A case in point is the public health care district of the Stockholm County Council in Sweden, one of the largest health care providers in Europe

Veidekke ASA: To build new regional offices in Bergen

Veidekke will start the construction of an environmentally certified office building with a 6,500 m2 floor area at a central location in Bergen. 55% of the building, which will be named Fantoftparken, is already leased, and will bring together Veidekke’s operations in the region. The construction contract is valued at NOK 158 million excluding VAT.In recent years Veidekke has increased its activities in Bergen. There has therefore long been a desire to gather the overall business in a new regional office with building, property and industrial operations. In partnership with Instanes Eiendom

Interim report January - June 2019

Quant releases the interim report for January - June 2019.April – June · Net sales for the period increased by 24% to EUR 49.1 (39.6) million due to the acquisition of Sataservice in August 2018. Organically, net sales declined by 1% compared to prior year · During the quarter no contracts were won or renewed, and nine contracts were lost which on balance affected the contract portfolio negatively. Portfolio run rate annualized net sales at the end of the quarter was EUR 186.6 million, compared to EUR 200.0 million in Q1 2019. Of the nine lost contracts, five were part of our

Studsvik to restructure its Consultancy Services business area

Studsvik has decided to restructure the Consultancy Services business area, which will be focused on our technical platforms for conditioning and volume reduction of radioactive waste. The restructuring means that only consultancy operations linked to the sale of licenses will be retained. The operations in England will include partnership in and services related to the low-level waste repository in Cumbria. The decision entails a substantial staff reduction in England. In connection with the new business approach, the business area will change its name to Studsvik Waste Management

Talkpool Interim report January-June 2019

APRIL 1st – JUN 30th 2019 · Net sales amounted to EUR 5 569 thousand (5 509), a 1.1 percent increase · EBITDA of EUR 52 thousand (375) and EBITDA margin of 0.9 percent (6.8) · EBIT of negative EUR 40 thousand (301) and EBIT margin of negative 0.7 percent (5.5) · Net earnings after tax of negative EUR 801 thousand (-58) · Net earnings after tax, adjusted for non-recognized FX gains, negative EUR 604 JAN 1st – JUN 30th 2019 · Net sales amounted to EUR 11 152 thousand (11 626), a 4.1 percent decrease · EBITDA of negative EUR 37 thousand (882) and EBITDA margin of

Realfiction Holding AB provides revised guidance for 2019

Realfiction Holding AB (“Realfiction”) reports that the timing of when its Sales Activities are expected to break-even has been pushed from any single month before the end of 2019 and into 2020 due to a temporary slow-down in the orders and revenue from its new Magic-as-a-Service concept.CEO Clas Dyrholm comments: “We are experiencing a temporary slow-down in the orders and revenue from our new Magic-as-a-Service concept. This is the case – in particular - in relation to our Exhibition vertical. We have seen that the sales generated via our partner-based go-to-market model within this

PowerCell delivers fuel cell system for tests in trucks at the German university RTWH Aachen

PowerCell Sweden AB has received an order for a MS-100 fuel cell system from the university RTWH Aachen for installation and tests in a medium-duty truck.The system will be used within the LiVe Project which aims at developing a cost-efficient electric drive-train solution for medium-duty distribution trucks. The LiVe Project is funded by the German Federal Ministry for the Environment, Nature Conservation, Construction and Nuclear Safety.The system, which is expected to be delivered during the fourth quarter 2019, will be installed in an 18 ton distribution truck to evaluate the use of

Mentice Q2 interim report 2019

Mentice AB (publ.) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, presents its interim report for second quarter 2019.   Comments from CEO First half year in line with our previous communications Net sales for the first half year increased to SEK 59.8 million (56.3) which is equivalent to a growth of 6,2%. We are confirming our short to medium term (next 3-5 years) financial target of a revenue growth of 30-40% per annum compounded, as stated in our first quarter interim report. For the current

2019 Q2 report, Period January-June for Panion Animal Health AB

Period April-June · Net sales: kSEK 0 (0). · Operating profit: kSEK -2 767 (-1 299). · Earnings per share: SEK -0,12 (-0,08). · Liquidity at the end of the period: kSEK 586 (15). Period January-June · Net sales: kSEK 0 (0). · Operating profit: kSEK -4 430 (-1 996). · Earnings per share: SEK -0,19 (-0,08). · Liquidity at the end of the period: kSEK 586 (15). Significant events after the end of the period:On July 10, 2019, it was announced that the shareholders of Panion Animal Health AB have accepted the offer from CombiGene AB with an acceptance rate

Saku Sipola starts as President and CEO of SRV Group Plc in September

SRV GROUP PLC             STOCK EXCHANGE RELEASE          29 AUGUST 2019    9.15 EET Saku Sipola starts as President and CEO of SRV Group Plc in September Appointed in June, M.Sc. (Tech) Saku Sipola will start in his role on 1 September 2019. SRV Group Plc’s Board of Directors appointed M.Sc. (Tech) Saku Sipola as President and CEO of SRV Group Plc in June. SRV announced that he will start in his new role at a later specified date, latest on 1 January 2020. Sipola joins SRV from SATO Corporation, where he has worked as the President and CEO since 2015. Prior to that Sipola, 50,

Borr Drilling Limited Announces Results for the Second Quarter 2019

Hamilton, Bermuda, August 29, 2019: Borr Drilling Limited (“Borr”, “Borr Drilling” or the “Company”) announces unaudited results for the three and six months ended June 30, 2019 Highlights in the second quarter 2019 · Operating revenues of $86.6 million, net loss of $103.2 million and Adjusted EBITDA of negative $4.9 million for the second quarter of 2019 · The results include a $31.5 million mark to market loss related to forward contracts the Company acquired in Rowan/Ensco (renamed Valaris PLC) in 2018. The share price of Valaris was as of June 30, 2019 $8.53. This relates to

Publication of interim financial report for January - June 2019

Nustay A/S (“Nustay”) hereby publishes financial report for the period of January - June 2019, showing a 40% increase in handled revenue in Q2 2019 compared to Q1 2019. The report is available as an attached document to this press release and on the Company’s website (www.nustay.com). Below is a summary of the report.Mathias Lundoe Nielsen, CEO of Nustay, comments: “Nustay experienced major growth in sales during Q1 and Q2 but we also faced a series of unforeseen challenges as part of this new chapter. The challenges were both related to integrations with our major marketing partners and

Anifrolumab Phase III trial meets primary endpoint

This announcement contains inside information 29 August 2019 07:00 BST Anifrolumab Phase III trial meets primary endpoint insystemic lupus erythematosus Positive top-line results from TULIP 2 trial demonstrate astatistically-significant and clinically-meaningful reduction indisease activity based on composite lupus assessment AstraZeneca today announced that the Phase III TULIP 2 trial for anifrolumab, a potential new medicine for the treatment of systemic lupus erythematosus (SLE), met its primary endpoint, achieving a statistically-significant and clinically-meaningful

AcadeMedia’s Year-end report July 2018 – June 2019

Fourth quarter (April – June 2019) · Net sales increased by 5.6 percent to SEK 3,162 million (2,993). Organic growth, including bolt-on acquisitions, was 5.3 percent. · Operating profit (EBIT) increased by 30.5 percent to SEK 218 million (167). Items affecting comparability in the period amounted to SEK -14 million (-40). Adjusted for items affecting comparability, operating profit was SEK 232 million (207). · Net profit for the period was SEK 148 million (111). · Cash flow from operating activities amounted to SEK 425 million (376). · The average number of children and

Plan for 510(k) submission specified - Q1 Interim Report: May-July 2019/2020

SEK thousands  Q1 19/20  Q1 18/19  May-April 18/19 Net sales  367  914  3,005 Operating profit (loss)  -6,097  -3,956  -21,718 Profit (loss) for the period  -6,068  -4,028  -21,556 Earnings per share, after dilution  -0.33  -0.23  -1.18  Significant events during the first quarter ·  Targeted new share issue for SEK 60 million to European and Swedish institutional investors and family offices ·  Positive study results from the EFECT study with DiviTum® published in the

IRRAS publishes Interim Report for the period January to June 2019

US sales started“During the second quarter, we reached a significant milestone by recording our first IRRAflow revenue in the United States (US). The US is the world´s largest market for neurosurgical procedures, and with the ongoing CE Mark recertification process, we have focused much of our team´s resources toward supporting a successful early market introduction in the US.” Kleanthis G. Xanthopoulos, Ph.D., President and CEO of IRRAS  Second quarter, April - June 2019 · Net revenue totaled SEK 1.1 million (0.1) · Operating loss (EBIT) amounted to SEK -40.7 million (-32.1)

There are no items matching the current filter
There are no more items matching the current filter
Back to top